NCT07322094
招募中
1 期
CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer
概览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events.
概览
简要总结
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
- •Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer
- •FIGO Stage III or IV
- •Positive for claudin 6 (CLDN6) expression
- •Adequate organ function
排除标准
- •Clear cell, mucinous, sarcomatous, mixed histology, low-grade/borderline, or non-epithelial ovarian cancers
- •Prior systemic treatment for the disease under study
- •Prior surgery
- •Prior radiation therapy to the abdomen or pelvis
- •Current recipient or receipt within 5-half-lives of C1D1 of chemotherapy, biologic/targeted therapy, immunomodulator therapy for any disease indication
- •Active, progressive, or symptomatic brain metastases
- •Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases
- •Pregnant or breastfeeding women
结局指标
主要结局
Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events.
时间窗: Treatment during Cycle 1 to Cycle 4 (Each cycle is 21 days)
Incidence of Grade greater than or equal to 3 (using CTCAE V5.0) treatment-emergent adverse event (TEAE) and related serious adverse event (SAE)
To assess the efficacy of neoadjuvant TORL-1-23 in combination with chemotherapy
时间窗: postoperative after Cycle 4 (Each cycle is 21 days)
Determination of percentage CRS3 score for each treatment arm
次要结局
- To assess the tolerability of TORL-1-23 in combination with chemotherapy(Treatment up to Cycle 8 (each cycle is 21 days))
- To characterize duration of benefit for TORL-1-23 plus chemotherapy(Measured up to 15 months after surgery)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.NCT07290166Fudan University42
尚未招募
1 期
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.2025-523146-27-00Innovative Molecules GmbH30
招募中
2 期
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerNCT07290621University of Chicago30
招募中
1 期
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsNCT07296341Shanghai Hengrui Pharmaceutical Co., Ltd.60
尚未招募
不适用
Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNCT07282873TYK Medicines, Inc219